Infection of primary CD4+ and CD8+ T lymphocytes by Epstein-Barr virus enhances human immunodeficiency virus expression

Journal of Virology

Volumn 70, Issue 10, 1996, Pages 7341-7346

  Guan, Mingxu ^a   Zhang, Ren De ^a,c   Wu, Brian ^b   Henderson, Earl E ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR;

ARTICLE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS CELL INTERACTION; VIRUS REPLICATION;

EID: 0029794296     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.10.7341-7346.1996     Document Type: Article

References (34)

1. Anagnostopoulos, I., M. Hummel, D. Kreschel, and H. Stein. 1995. Morphology, immunophenotype and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood 85:744-750.
2. Beisel, C., J. Tanner, T. Matsuo, D. Thorley-Lawson, F. Kezdy, and E. Kieff. 1985. Two major outer envelope glycoproteins of Epstein-Barr virus are encoded by the same gene. J. Virol. 54:665-674.
3. Birkenback, M., X. Tong, L. E. Bradbury, T. F. Tedder, and E. Kieff. 1992 Characterization of an Epstein-Barr virus receptor on human epithelial cells. J. Exp. Med. 176:1405-1414.
4. Brooks, L., Q. Y. Yao, A. B. Rickinson, and L. S. Young. 1992. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J. Virol. 66:2689-2697.
5. Chen, C.-L., R. H. Sadler, D. M. Walling, I.-J. Su, H.-C. Hsieh, and N. Raab-Traub. 1993. Epstein-Barr virus (EBV) gene expression in EBV-positive peripheral T-cell lymphomas. J. Virol. 67:6303-6308.
6. Cooper, D. A., P. O. Pehrson, C. Pedersen, M. Moroni, E. Oksenhendler, W. Rozenbaum, N. Clumeck, V. Faber, W. Stille, B. Hirschel, C. Farthing, R. Doherty, and J. M. Yeo. 1993. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind, randomized trial. AIDS 7:197-207.
7. Diaz, J.-J., M. D. Dodon, N. Schaerer-Uthurralt, D. Simonin, K. Kindbeiter, L. Gazzolo, and J. J. Madjar. 1996. Post-transcriptional transactivation of human retroviral envelope glycoprotein expression by herpes simplex virus UsII protein. Nature (London) 379:273-277.
8. Fingeroth, J. D., M. L. Clabby, and J. D. Strominger. 1988. Characterization of a T-lymphocyte Epstein-Barr virus/C3d receptor (CD21). J. Virol. 62: 1442-1447.
9. Fischer, E., C. Delibrias, and M. D. Kazatchkine. 1991. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T lymphocytes. J. Immunol. 146:865-869.
10. Frade, R., M. Barel, B. Ehlin-Henriksson, and G. Klein. 1985. gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor. Proc. Natl. Acad. Sci. USA 82:1490-1493.
11. Hedrick, J. A., D. Watry, C. Speiser, P. O'Donnell, J. D. Lambris, and C. D. Tsoukas. 1992. Interaction between Epstein-Barr virus and a T cell line (HSB-2) via a receptor phenotypically distinct from complement receptor type 2. Eur. J. Immunol. 22:1123-1131.
12. Henderson, E. E. 1978. Host cell reactivation of Epstein-Barr virus in normal and repair-defective leukocytes. Cancer Res. 38:3256-3263.
13. Henderson, E. E., Y. Y. Yang, R. D. Zhang, and M. Bealer. 1991. Altered HIV expression and EBV-induced transformation in coinfected PBLs and PBL subpopulations. Virology 182:186-198.
14. Holguin, M. H., C. B. Kurtz, C. J. Parker, J. J. Weis, and J. H. Weis. 1990. Loss of human CR1- and murine Crry-like exons in human CR2 transcripts due to CR2 gene mutations. J. Immunol. 145:1776-1781.
15. Joab, I., H. Triki, J. de Saint Martin, M. Perricaudet, and J. C. Nicolas. 1991. Detection of anti-Epstein-Barr virus trans-activator (ZEBRA) antibodies in sera from patients with human immunodeficiency virus. J. Infect. Dis. 163:53-56.
16. Kellogg, D. E., and S. Kwok. 1990. Detection of human immunodeficiency virus, p. 337-347. In M. A. Innis, D. H. Gelfand, J. J. Sninsky, and T. J. White (ed.), PCR protocols: a guide to methods and applications Academic Press, Berkeley, Calif.
17. Khanna, R., S. R. Burrows, and D. J. Moss. 1995. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol. Rev. 59:387-405.
18. Lin, J.-C. 1993. The Epstein-Barr virus DNA polymerase transactivates the human immunodeficiency virus type 1 5′ long terminal repeat. Biochem. Biophys. Res. Commun. 195:242-249.
19. Martin, D. R., A. Yuryev, K. R. Kalli, D. T. Fearon, and J. M. Ahearn. 1991. Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2. J. Exp. Med. 174:1299-1311.
20. Moore, M. D., N. R. Cooper, B. F. Tack, and G. R. Nemerow. 1987. Molecular cloning of the cDNA encoding the Epstein-Barr virus/C3d receptor (complement receptor type 2) of human B lymphocytes. Proc. Natl. Acad. Sci. USA 84:9194-9198.
21. Neraerow, G. R., C. Mold, V. K. Schwend, V. Tollefson, and N. R. Cooper. 1987. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J. Virol. 61:1416-1420.
22. Paterson, R. L. K., C. Kelleher, T. D. Amankonah, J. E. Streib, J. W. Xu, J. F. Jones, and E. W. Gelfand. 1995. Model of Epstein-Barr virus infection of human thymocytes: expression of viral genome and impact on cellular receptor expression in the T-lymphoblastic cell line, HPB-ALL. Blood 85:456-464.
23. Quinlivan, E. B., E. Holley-Guthrie, E.-C. Mar, M. S. Smith, and S. Kenney. 1990. The Epstein-Barr virus BRLF1 immediate-early gene product transactivates the human immunodeficiency virus type 1 long terminal repeat by a mechanism which is enhancer independent. J. Virol. 64:1817-1820.
24. Sample, J., L. Young, B. Martin, T. Chatman, E. Kieff, A. Rickinson, and E. Kieff. 1990. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J. Virol. 64:4084-4092.
25. + (cytotoxic/suppressor) T lymphocytes. J. Gen. Virol. 71:379-386.
26. Schattner, A., N. Hanuka, B. Sarov, I. Sarov, Z. Handzel, and Z. Benrwich. 1991. Sequential serological studies of homosexual men with and without HIV infection. Epstein-Barr virus activation preceding and following HIV seroconversion. Clin. Exp. Immunol. 85:209-213.
27. Tierney, R. J., N. Steven, L. S. Young, and A. B. Rickinson. 1994. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J. Virol. 68:7374-7385.
28. Titti, F., A. Borsetti, M. Federico, U. Testa, E. Meccia, P. Samoggia, C. Peschle, P. Verani, and G. B. Rossi. 1992. Extrachromosomal human immunodeficiency virus type 1 DNA forms in fresh peripheral blood lymphocytes and in two interleukin-2-independent T cell lines derived from peripheral blood lymphocytes of an asymptomatic seropositive subject. J. Gen. Virol. 73:3087-3097.
29. Tsoukas, C. D., and J. D. Lambris. 1993. Expression of EBV/C3d receptors on T cells: biological significance. Immunol. Today 14:56-59.
30. Walker, C. M., A. L. Erickson, F. C. Hsueh, and J. A. Levy. 1991. Inhibition of human immunodeficiency virus replication in acutely infected CD4+ cells by CD8+ cells involves a noncytotoxic mechanism. J. Virol. 65:5921-5927.
31. Walker, C. M., D. J. Moody, D. P. Stites, and J. A. Levy. 1989. CD8+ T lymphocytes control of HIV replication in cultured CD4+ cells varies among infected individuals. Cell. Immunol. 119:470-475.
32. Yoneda, N., E. Tatsumi, M. Kawanishi, K. Teshigawara, S. Masuda, Y. Yamamura, A. Inui, G. Yoshino, M. Oimomi, S. Baba, and N. Yamaguchi. 1990. Detection of Epstein-Barr virus genome in benign polyclonal proliferative T cells of a young male patient. Blood 76:172-177.
33. Youle, M. S., B. G. Gazzard, M. A. Johnson, D. A. Cooper, J. F. Hoy, H. Busch, B. Ruf, P. D. Griffiths, S. L. Stephenson, M. Dancox, and A. Bell. 1994. Effects of high-dose acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double-blind, placebo-controlled study. AIDS 8:641-649.
34. Zalani, S., E. A. Holley-Guthrie, D. E. Gutsch, and S. C. Kenney. 1992. The Epstein-Barr virus immediate-early promoter BRLF1 can be activated by the cellular SpI transcription factor. J. Virol. 66:7282-7292.